news

BenevolentAI hires new head of Cheminformatics from The Institute of Cancer Research

BenevolentAI announced today it has hired Dr Nathan Brown, as its new Head of Cheminformatics following the promotion of Mark Davies…

Cheminformatics

BenevolentAI announced today it has hired Dr Nathan Brown BSc (Hons) FRSC, as its new Head of Cheminformatics following the promotion of Mark Davies from Head of Cheminformatics to Vice President of Biomedical Informatics earlier in the year.  

Dr Brown joined the Institute of Cancer Research (ICR), London in 2007 where he founded and led the new In Silico Medicinal Chemistry Group which focused on medicinal chemistry research towards novel cancer treatments. Dr Brown holds a degree in computing from Robert Gordon University, Aberdeen and conducted his doctoral research in the field of Cheminformatics at the University of Sheffield.  Following his PhD he was awarded a Marie Curie Fellowship for two years working with Avantium in Amsterdam and subsequently one of the first to be awarded a prestigious Presidential Research Fellowship for three years, by Professor Mark Fishman, Global Head of Research at the Novartis Institutes for BioMedical Research.

With extensive experience as a software designer Dr Brown has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology. Furthermore Dr Brown is a recent recipient of the Corwin Hansch Award for contributions to computational chemistry. 

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

Jackie Hunter, CEO of Benevolent Bío, the bioscience subsidiary of BenevolentAI, commented

“Nathan Brown is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry.  He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published.  We are delighted to have Nathan on board.”  

Leave a Reply

Your email address will not be published. Required fields are marked *